Aetna is a CVS Health subsidiary. Coverage of GLP-1 medications is generally less generous than peer commercial insurers, with strict PA criteria for weight indications.
Type 2 diabetes coverage
Generally covered for T2D. Typical copay $30–$100/month with PA.
Weight management coverage
Aetna applies strict PA criteria. Many plans require documented 6+ months of lifestyle modification with weight outcomes documented before approving Wegovy/Zepbound. Some plans exclude weight management entirely.
Cardiovascular indication coverage
Coverage of Wegovy under CV indication is being added; PA criteria still rigorous.
OSA indication coverage
Coverage of Zepbound for OSA is following standard PA pathways for the OSA indication.
Prior authorization criteria (typical)
Aetna PA criteria are typically: BMI ≥30 or BMI ≥27 with documented comorbidity; documented 6+ months of lifestyle modification with weight tracking; documented commitment to ongoing lifestyle.
If your plan excludes weight-management drugs
Strict PA makes denials common; carefully prepare medical necessity documentation; appeal denials; consider cash-pay alternatives.
How to verify
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
Cash-pay alternative
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. NexLife, our editorial pick, lists compounded semaglutide at $95–$109 and tirzepatide at $115–$129 a month depending on plan length (prices as of November 6, 2026); see the NexLife review.